ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / GRAL / earnings
RDNT (57) BLLN (70) CON (68) CDNA (71) ⌘ Pro Terminal →

GRAIL Inc. (GRAL) Next Earnings Date & Expected ±12.5% Move

$133.76 -6.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $131.88

GRAIL Inc. (GRAL) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $6.41B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GRAL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GRAL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, GRAIL Inc. (NASDAQ: GRAL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $133.76 (-6.74% 1D, market cap $6.41B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, GRAL ranks #211 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GRAL compare to RDNT and BLLN in the Health Care sector?
▼

Within the Health Care sector (Medical Specialities), GRAL carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -18.0%. By comparison, RDNT (RadNet Inc.) holds a D+ grade (57/100 RQD, P/E N/A, ROIC 3.5%, cap $5.78B) and BLLN (BillionToOne Inc.) posts a B- grade (70/100 RQD, P/E N/A, ROIC 2.9%, cap $5.35B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GRAL?
▼

Per GRAL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001699031), GRAIL Inc. generated $147.2M in revenue (+17.2% YoY), -$408.4M in net income, and -$299.9M in free cash flow against $2.92B in total assets and $154.9M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $131.89 (-1.40%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510054
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+
Cash (7)Whales (18)SEC (14)Macro (9)CEO (6)
Each axis scored 0–20
12M PRICE TARGET CONE-1.8% Base Target
$175 Bull$131 Base$102 Bear
📬 FREE GRAL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GRAL)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (54/100 Composite)
🔍 WHY GRAL SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (33% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (26% of score)

Altman Z-Score 7.26 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)

Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
62
Grade C+$139.70-5.1% Next Q
Q2 (-2Q)
59
Grade C$132.60+19.1% Next Q
Q3 (-1Q)
57
Grade C$157.88-15.3% Next Q
Current
54
Grade D+$133.76-0.7% Hist 90D α
Trajectory: C+ (62) → D+ (54)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GRAL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GRAL currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($116.44) and Max Pain ($140.45) forces dealer call-delta covering toward $174.80.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GRAL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GRAL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 54%NO 46%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$16.72 Expected Swing
$117.04 (-12.5%)Spot $133.76$150.48 (+12.5%)
MODEL EARNINGS SETUP GAUGE

GRAL Quantitative Pre-Earnings Setup: 54/100

Trailing EPS: $-9.14 • YoY Revenue Growth: 17.2%

Model Bullish Setup (54/100)Model Risk Weight (46/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$147.2M-$408.4M-$299.9M52%
FY 20242024-12-31$125.6M-$2.03B-$582.4M52%
FY 20232023-12-31$93.1M-$1.47B-$600.0M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GRAL)

  • ✓Walkthrough of GRAL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
GRAL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +140.32%▲ ASCENDING CHANNEL
2026-11-03O $158.9H $158.9L $133.8C $133.8VOL 1.07M
RES: $187.0SUP: $91.53SMA50: $116.4SMA200: $78.89
$174.6$140.9$107.3$73.62$39.96RES $187.0SUP $91.53$133.82026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GRAL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GRAL Butterfly Map → + Track GRAL →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
15.7%/yr Implied 5Y Growth

vs. +17.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on GRAL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GRAL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GRAL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GRAL)

Health Care Rank #211 of 1015 ⚔️ RDNT vs GRAL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GRAL vs. RDNT, BLLN, CON, CDNA)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, GRAIL Inc. (GRAL) ranks #211 by composite RQD confidence (54/100, grade D+) and #140 by equity capitalization ($6.41B). Within this direct 5-issuer industry benchmark cohort, CON leads on earnings valuation at 31.6x trailing P/E, while CON leads on capital efficiency and profitability with 19.7% ROIC and — gross margin. CDNA currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with GRAL at 54/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GRAL ACTIVE
GRAIL Inc.
D+ 54/100 — — -18.0% -6.74% $6.41B Benchmark Subject
RDNT
RadNet Inc.
D+ 57/100 — — 3.5% -0.53% $5.78B /rdnt-vs-gral →
BLLN
BillionToOne Inc.
B- 70/100 — 68.3% 2.9% -2.57% $5.35B /blln-vs-gral →
CON
Concentra Group Holdings Parent Inc.
C+ 68/100 31.6x — 19.7% -0.12% $5.15B /con-vs-gral →
CDNA
CareDx Inc.
B- 71/100 — — -8.2% -1.75% $4.59B /cdna-vs-gral →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001699031 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), GRAIL Inc. (GRAL) reported GAAP revenue of $147.2M (+17.2% vs. FY2024 revenue of $125.6M , and +58.1% cumulative change since FY2023) , GAAP net income of -$408.4M, operating cash flow of -$299.0M, and free cash flow of -$299.9M (+48.5% YoY). On the balance sheet, GRAL closed FY2025 with $2.92B in total assets against $154.9M in total debt (Altman Z-Score: 7.26, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $147.2M -$408.4M -$299.0M -$299.9M $2.92B $154.9M
FY2024 (FY) 2024-12-31 $125.6M -$2.03B -$577.2M -$582.4M $2.98B $216.0M
FY2023 (FY) 2023-12-31 $93.1M -$1.47B -$595.8M -$600.0M $3.90B $913.6M

3. GRAL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GRAL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, GRAIL Inc. (NASDAQ: GRAL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $133.76 (-6.74% 1D, market cap $6.41B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, GRAL ranks #211 in composite RQD confidence.

How does GRAL compare to RDNT and BLLN in the Health Care sector?

Within the Health Care sector (Medical Specialities), GRAL carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -18.0%. By comparison, RDNT (RadNet Inc.) holds a D+ grade (57/100 RQD, P/E N/A, ROIC 3.5%, cap $5.78B) and BLLN (BillionToOne Inc.) posts a B- grade (70/100 RQD, P/E N/A, ROIC 2.9%, cap $5.35B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GRAL?

Per GRAL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001699031), GRAIL Inc. generated $147.2M in revenue (+17.2% YoY), -$408.4M in net income, and -$299.9M in free cash flow against $2.92B in total assets and $154.9M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GRAL trading relative to its 50-day, 200-day, and 52-week technical levels?

GRAL last traded at $133.76 (-6.74% on volume of 983,307 shares), positioning the stock +14.87% above its 50-day simple moving average ($116.44) and +69.55% above its 200-day simple moving average ($78.89). Across its 52-week range of $41.50 to $166.48, GRAL sits at the 73.8% percentile with a 14-day RSI of 54.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($117.04 to $150.48).

Direct Sub-Reports: GRAL RQD Cockpit GRAL 12M Forecast GRAL Earnings & Move GRAL Dividends & DRIP GRAL Insiders & 13F GRAL Whale Options GRAL Profit Sankey GRAL News & Why
ROARABLE RATING BRIEF • RQD 54/100 (D+) ✓ SEC XBRL & RQD VERIFIED

GRAL — GRAIL Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

GRAIL Inc. (GRAL) earns a live Roarable RQD composite score of 54/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $133.76 (-6.74% 1D, market capitalization $6.41B).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -18.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -4.23%.
  • Whale 13F & Options Flow (18/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 7.26, Piotroski F-Score of 6/9, and Debt/Equity of 0.06x.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Common Stock (GRAL) is a NASDAQ-listed issuer in the Health Care sector and the Medical Specialities industry, with a market capitalization of $7.1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), GRAIL Inc. (GRAL) reported $147.2M in annual revenue (up from $125.6M in FY2024, +17.2% YoY) and -$408.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($93.1M revenue, -$1.47B net income) through FY2025, GRAL scaled operating cash flow to -$299.0M and free cash flow to -$299.9M, backed by $2.92B in total assets against $154.9M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 54/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -4.23% and institutional whale pillar of 18/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 18/20, sustained execution supports upside toward the upper end of the $41.50 – $166.48 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical Specialities (Health Care), GRAL carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can GRAL sustain or expand its -60.0% operating margin and -18.0% ROIC against Medical Specialities peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $147.2M and free cash flow of -$299.9M, how will capital allocation balance growth reinvestment against $154.9M in total debt?
  • Key Question #3: How sensitive is GRAL's 22.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

GRAL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for GRAIL Inc. (GRAL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GRAL Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GRAL Bull vs. Bear Conversation Board — What's Your Call at $133.76?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GRAL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on GRAL:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $176.42 (+23.0%)
📌 Pinned Debate

Institutional flow scores 18/20 and the balance sheet is supportive with Debt/Equity of 0.06 and an Altman Z-Score of 7.26.

The street is overcomplicating GRAIL Inc. (GRAL). Institutional flow scores 18/20 and the balance sheet is supportive with Debt/Equity of 0.06 and an Altman Z-Score of 7.26.. With an RQD score of 54/100 (D+) and Forensic Balance Sheet at 14/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $154.90.

EarningsSniper 🐂 BULL

@SkepticalCFA Shorting a 18/20 institutional whale-flow stock at $143.43 is dangerous when funds are rotating into Health Care.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $109.01 (-24.0%)
Spot @ $143.43

Negative ROIC of -18% and a negative FCF yield of -4.23% leave the cash engine scored 7/20 despite revenue growing to $147.2M.

Sitting on the sidelines or leaning short GRAL above $143.43. Negative ROIC of -18% and a negative FCF yield of -4.23% leave the cash engine scored 7/20 despite revenue growing to $147.2M.. Until Fundamental Cash Engine (7/20) and FCF yield (-4.23%) inflect higher, upside is capped near $166.48.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%